Royalty Pharma Announces Marshall Urist, MD, PhD, Joins Management Team

NEW YORK, July 19, 2013 /PRNewswire/ -- Royalty Pharma is pleased to announce that Marshall Urist, MD, PhD, has joined the company as Vice President, Research and Investments. 

Dr. Urist spent the last eight years at Morgan Stanley in equity research, most recently as Executive Director and the senior biotechnology analyst. Earlier at Morgan Stanley, he covered the life science tools and diagnostics sectors, where he was recognized in Institutional Investor's All-America Research Team. 

"We are excited to have Marshall join our team. He has had a distinguished career on Wall Street, and this experience coupled with his deep analytical skills make him an excellent addition to Royalty Pharma," said Pablo Legorreta, Founder and CEO of Royalty Pharma.

Dr. Urist graduated Phi Beta Kappa from Johns Hopkins University and holds a MD and PhD from Columbia University.

About Royalty Pharma

Royalty Pharma is the industry leader in acquiring royalty interests in marketed and late stage biopharmaceutical products. With over $10 billion in assets, Royalty Pharma owns royalty interests in 41 marketed and late stage biopharmaceutical products, including Abbott's Humira®, Johnson and Johnson'sRemicade® and Prezista®, Gilead's Atripla®, Truvada®, Complera® and Emtriva®, Pfizer's Lyrica®, Amgen's Neupogen® and Neulasta®, Genentech'sRituxan®, Astella's Lexiscan®, Merck's Januvia/Janumet®, Roche's Mircera®, UCB's Cimzia®, Biogen Idec's Tecifidera® and Pharmacyclics' ibrutinib. Additional company information is available at royaltypharma.com.

Royalty Pharma | RP Management LLC 
Investor Relations 
+ 1 (212) 883-0200 
[email protected]

Suggested Articles

The biotech behind AstraZeneca and the University of Oxford’s late-stage pandemic vaccine has hired Margaret (Meg) Marshall, M.D., as its new CMO.

On the heels of a merger and $60 million private offering, Compass is looking to go public. It filed to raise up to $50 million in its Nasdaq IPO.

he results suggest V114 provides broader protection from pneumococcal bacteria than Prevnar 13 does, positioning Merck to muscle in on Pfizer’s turf.